You are receiving this message since your browser does not support Java Script or you have Java Scripts disabled. The following disclaimer is provided as an alternative to the information that would normally be seen on your monitor when you click on a link to a non-federal site.

"You are now leaving the NIDDK website. The NIDDK is not responsible for the content of web pages found on this linked website. Links to nonfederal organizations are provided solely as a service to our users. These links do not indicate an endorsement of these organizations by NIDDK or the federal government."


Type 1 Diabetes Clinical Trials and Clinical Research

The below list only includes type 1 diabetes clinical studies that are supported by the Type 1 Diabetes Special Diabetes Program. To learn about additional type 1 diabetes clinical trials, please visit http://www.clinicaltrials.gov. The National Institute of Allergy and Infectious Diseases (NIAID) also sponsors clinical trials related to type 1 diabetes. Find out more about NIAID-supported type 1 diabetes studies.

Study Name

Who Can Participate?
Type 1 Diabetes TrialNet

Pathway to Prevention Study (TrialNet)

To participate in the screening phase of the Pathway to Prevention Study, you must be:

  • 1 to 45 years of age and have a brother, sister, child, or parent with type 1 diabetes; OR
  • 1 to 20 years of age and have a cousin, aunt, uncle, niece, nephew, half-sibling, or grandparent with type 1 diabetes.

    • In general, type 1 diabetes is assumed if it developed before age 40 and required insulin injections within a year of diagnosis.



    Oral Insulin Study (TrialNet)

    To be screened for the study, you must be:

  • 1 to 45 years of age and have a brother, sister, child, or parent with type 1 diabetes; OR
  • 1 to 20 years of age and have a cousin, aunt, uncle, niece, nephew, half-sibling, or grandparent with type 1 diabetes.



    • Anti-CD3 mAb for Prevention of Type 1 Diabetes in Relatives At Risk (Teplizumab)

    You can be screened for the study if:

  • You have been referred by TrialNet’s Pathway to Prevention Study
  • You are 8 to 45 years old (enrollment will initially be limited to people 16-45 years of age)



    • Search for Diabetes in Youth

    SEARCH for Diabetes in Youth (SEARCH)

    Children and youth who are under age 20 when they were diagnosed with diabetes may be eligible to join. Eligibility may depend on the place the child or young adult resides or the place where health care is received.



    Clinical Islet Transplantation Consortium

    Efficacy of Islet after Kidney Transplantation (CIT-06)

    In general, to participate in this study, one must be 18-68 years of age, diagnosed with type 1 diabetes before age 40, be insulin dependent for more than 5 years, and have received a kidney transplant. There are more specific inclusion and exclusion criterion for participation in this study, which can be discussed with the study contact.



    Islet Transplantation in Type 1 Diabetes with LEA29Y Maintenance Therapy (CIT-04)

    You may be enrolled into this study, if you:

  • are 18 to 65 years of age;
  • have been diagnosed with type 1 diabetes with symptoms prior to age 40;
  • are insulin dependent for at least 5 years, with three or more injections each day or on insulin pump therapy;
  • have blood tests that show your body does not make insulin;
  • are managing your diabetes daily, by checking you blood sugar at least three times a day;
  • have had at least one episode of severe hypoglycemia in the past year where you needed the help of another person; and
  • have hypoglycemia unawareness, a condition in which you no longer experience the usual warning signs of hypoglycemia.



    		•

    Open Label, Randomized Multi-Center Study to Evaluate Safety and Efficacy of Low Molecular Weight Sulfated Dextran (LMW-SD) in Islet Transplantation (CIT-01)

    In general, to participate in this study, one must be 18-65 years of age, diagnosed with type 1 diabetes before age 40, and be insulin dependent for more than 5 years. There are more specific inclusion and exclusion criterion for participation in this study, which can be discussed with the study contact.



    Back to Top



    Return to Type 1 Diabetes Studies Home Page

    Last Updated:

    General Inquiries may be addressed to:
    Office of Communications and Public Liaison
    NIDDK, NIH
    Building 31, Rm 9A06
    31 Center Drive, MSC 2560
    Bethesda, MD 20892-2560 USA
    For information about NIDDK programs: 301.496.3583